Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature.

about

Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature.

Item

http://www.wikidata.org/entity/Q36028694

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Human Epidermal Growth Factor ...... and Review of the Literature.

@ast

Human Epidermal Growth Factor ...... and Review of the Literature.

@en

type

Item

label

Human Epidermal Growth Factor ...... and Review of the Literature.

@ast

Human Epidermal Growth Factor ...... and Review of the Literature.

@en

prefLabel

Human Epidermal Growth Factor ...... and Review of the Literature.

@ast

Human Epidermal Growth Factor ...... and Review of the Literature.

@en

P1476

Human Epidermal Growth Factor ...... and Review of the Literature.

@en

P2093

Caio Coelho Netto

http://www.w3.org/2001/XMLSchema#string

Marcos Belotto de Oliveira

http://www.w3.org/2001/XMLSchema#string

Renata D'Alpino Peixoto

http://www.w3.org/2001/XMLSchema#string

Roberto El Ibrahim

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant chemotherapy for small intestine adenocarcinoma

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Trastuzumab--mechanism of action and use in clinical practice

The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995.

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Biologic and therapeutic role of HER2 in cancer.

Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

P304

285-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000437257

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Virginia Moreira Braga

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281635530

http://www.w3.org/2001/XMLSchema#string

P698

26351435

http://www.w3.org/2001/XMLSchema#string

P932

4560331

http://www.w3.org/2001/XMLSchema#string